Search

We present observational results of water vapor maser emission with our high-sensitivity 22 GHz very long baseline interferometry (VLBI) imaging of the Seyfert galaxy NGC 1068. In this galaxy, there are the following four nuclear radio sources; NE, C, S1, and S2. Among them, the S1 component has been identified as the nucleus while the C component has been considered as attributed to the radio jet. In our VLBI observation, we find the following two types of water maser emission at the S1 component. One is a linearly aligned component that is considered as an edge-on disk with an inner radius of 0.62 pc. The dynamical mass enclosed within the inner radius was estimated to be 1.5 × 107  M ⊙ by assuming the circular Keplerian motion. Note, however, that the best-fitting rotation curve shows a sub-Keplerian rotation (v ∝ r −0.24±0.10). The other is water maser emission distributed around the rotating disk component up to 1.5 pc from the S1 component, suggesting a bipolar outflow from the S1 component. Further, we detected water maser emission in the C component for the first time with VLBI, and discovered a ring-like distribution of water maser emission. It is known that a molecular cloud is associated with the C component (both HCN and HCO+ emission lines are detected by ALMA). Therefore, the ring-like maser emission can be explained by the jet collision to the molecular cloud. However, if these ring-like water masing clouds constitute a rotating ring around the C component, it is likely that the C component also has a supermassive black hole with a mass of ∼106  M ⊙ that could be supplied from a past minor merger of a nucleated satellite galaxy. [ABSTRACT FROM AUTHOR]

Aims: To evaluate the coronavirus disease 2019 pandemic's impact on pregnancy outcomes in a Japanese rural area. Methods: This retrospective study focused on the periods between March 1, 2020, and February 28, 2021 (during the coronavirus disease 2019 pandemic), and January 1, 2017, and December 31, 2019. Singleton pregnancies delivered at or after 22 gestational weeks were included. Preterm delivery, low‐birth‐weight, and small‐for‐gestational‐age infant rates during the pandemic were compared to those in the preceding 3 years. Results: In the pandemic and control groups, 1650 and 5762 pregnant women were included, respectively. Two pregnant women with coronavirus disease 2019 were identified (0.1%). There were no significant intergroup differences in preterm delivery rates (control, 4% vs. pandemic, 3.3%; difference: −0.7% [95% confidence interval: −1.7%–0.3%], p = 0.22). The low‐birth‐weight rate tended to decrease; however, the difference was insignificant (7.9% vs. 6.5%; difference: −1.4% [95% confidence interval: −2.8–0%], p = 0.06). The small‐for‐gestational‐age infant rate was significantly lower in the pandemic than in the control group (7.3% vs. 5.2%; difference: −2.1% [95% confidence interval: −3.3–0.8%], p < 0.01). However, the interrupted time series analysis showed no significant trend. Conclusions: There were no significant changes in the rates of preterm delivery, low‐birth‐weight infants, and small‐for‐gestational‐age infants during the pandemic's first year compared to those in the preceding 3 years. Behavioral changes, such as "stay‐at‐home" measures, may not improve pregnancy outcomes in Japan. [ABSTRACT FROM AUTHOR]

Although intranasal oxytocin is expected to be a novel therapy for the core symptoms of autism spectrum disorder, which has currently no approved medication, the efficacy of repeated administrations was inconsistent, suggesting that the optimal dose for a single administration of oxytocin is not optimal for repeated administration. The current double-blind, placebo-controlled, multicentre, crossover trial (ClinicalTrials.gov Identifier: NCT03466671) was aimed to test the effect of TTA-121, a new formulation of intranasal oxytocin spray with an enhanced bioavailability (3.6 times higher than Syntocinon® spray, as assessed by area under the concentration-time curve in rabbit brains), which enabled us to test a wide range of multiple doses, on autism spectrum disorder core symptoms and to determine the dose-response relationship. Four-week administrations of TTA-121, at low dose once per day (3 U/day), low dose twice per day (6 U/day), high dose once per day (10 U/day), or high dose twice per day (20 U/day), and 4-week placebo were administered in a crossover manner. The primary outcome was the mean difference in the reciprocity score (range: 0-14, higher values represent worse outcomes) on the Autism Diagnostic Observation Schedule between the baseline and end point of each administration period. This trial with two administration periods and eight groups was conducted at seven university hospitals in Japan, enrolling adult males with high-functioning autism spectrum disorder. Enrolment began from June 2018 and ended December 2019. Follow-up ended March 2020. Of 109 males with high-functioning autism spectrum disorder who were randomized, 103 completed the trial. The smallest P-value, judged as the dose-response relationship, was the contrast with the peak at TTA-121 6 U/day, with inverted U-shape for both the full analysis set (P = 0.182) and per protocol set (P = 0.073). The Autism Diagnostic Observation Schedule reciprocity score, the primary outcome, was reduced in the TTA-121 6 U/day administration period compared with the placebo (full analysis set: P = 0.118, mean difference = -0.5; 95% CI: -1.1 to 0.1; per protocol set: P = 0.012, mean difference = -0.8; 95% CI: -1.3 to -0.2). The per protocol set was the analysis target population, consisting of all full analysis set participants except those who deviated from the protocol. Most dropouts from the full analysis set to the per protocol set occurred because of poor adherence to the test drug (9 of 12 in the first period and 8 of 15 in the second period). None of the secondary clinical and behavioural outcomes were significantly improved with the TTA-121 compared with the placebo in the full analysis set. A novel intranasal spray of oxytocin with enhanced bioavailability enabled us to test a wide range of multiple doses, revealing an inverted U-shape dose-response curve, with the peak at a dose that was lower than expected from previous studies. The efficacy of TTA-121 shown in the current exploratory study should be verified in a future large-scale, parallel-group trial. [ABSTRACT FROM AUTHOR]